Medical Stocks

Conmed Corp Valuation – August 2018 $CNMD

Company Profile (excerpt from Reuters): CONMED Corporation, incorporated on February 10, 1970, is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company’s product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company’s products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors.

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of CNMD – August 2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $2,187,212,094 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 2.15 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 210.00% Pass
6. Moderate PEmg Ratio PEmg < 20 51.15 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 3.57 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 2.15 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 2.42 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

 

Stage 2: Determination of Intrinsic Value

EPSmg $1.57
MG Growth Estimate 6.75%
MG Value $34.59
Opinion Overvalued
MG Grade C-
MG Value based on 3% Growth $22.79
MG Value based on 0% Growth $13.36
Market Implied Growth Rate 21.32%
Current Price $80.40
% of Intrinsic Value 232.42%

CONMED Corporation is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor is only concerned with the level of debt relative to the net current assets. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $1.08 in 2014 to an estimated $1.57 for 2018. This level of demonstrated earnings growth does not support the market’s implied estimate of 21.32% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into CONMED Corporation revealed the company was trading above its Graham Number of $33.13. The company pays a dividend of $0.8 per share, for a yield of 1% Its PEmg (price over earnings per share – ModernGraham) was 51.15, which was above the industry average of 44.66. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-12.78.

CONMED Corporation receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$12.78
Graham Number $33.13
PEmg 51.15
Current Ratio 2.15
PB Ratio 3.57
Current Dividend $0.80
Dividend Yield 1.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 3/1/2018
Total Current Assets $342,378,000
Total Current Liabilities $159,300,000
Long-Term Debt $442,408,000
Total Assets $1,350,034,000
Intangible Assets $821,515,000
Total Liabilities $707,406,000
Shares Outstanding (Diluted Average) 28,573,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $2.16
Dec2017 $1.97
Dec2016 $0.52
Dec2015 $1.09
Dec2014 $1.16
Dec2013 $1.28
Dec2012 $1.41
Dec2011 $0.03
Dec2010 $1.05
Dec2009 $0.42
Dec2008 $1.37
Dec2007 $1.43
Dec2006 -$0.45
Dec2005 $1.08
Dec2004 $1.11
Dec2003 $1.10
Dec2002 $1.23
Dec2001 $1.00
Dec2000 $0.83
Dec1999 $1.17
Dec1998 $0.77

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $1.57
Dec2017 $1.25
Dec2016 $0.96
Dec2015 $1.12
Dec2014 $1.08
Dec2013 $0.98
Dec2012 $0.84
Dec2011 $0.65
Dec2010 $0.90
Dec2009 $0.80
Dec2008 $0.97
Dec2007 $0.79
Dec2006 $0.59
Dec2005 $1.11
Dec2004 $1.10
Dec2003 $1.08
Dec2002 $1.05

Recommended Reading:

Other ModernGraham posts about the company

CONMED Corporation Valuation – Initial Coverage $CNMD

Other ModernGraham posts about related companies

Invacare Corp Valuation – July 2018 $IVC
Select Medical Holdings Corp Valuation – July 2018 $SEM
Chemed Corp Valuation – July 2018 $CHE
Inogen Inc Valuation – July 2018 $INGN
Tenet Healthcare Corp Valuation – June 2018 $THC
Universal Health Services Inc Valuation – June 2018 $UHS
Dentsply Sirona Inc Valuation – June 2018 $XRAY
IDEXX Laboratories Inc Valuation – June 2018 $IDXX
Hologic Inc Valuation – June 2018 $HOLX
Mettler-Toledo International Inc Valuation – June 2018 $MTD

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top